Screening PSA levels at aged 65-69 may inform the decision to continue or discontinue prostate cancer screening after age 70 years, regardless of patient race and ethnicity. The absolute risks of ...
A single PSA test at midlife may identify men with a low risk of prostate cancer for up to 20 years, supporting longer screening intervals. Men with a low baseline PSA level at midlife have a low risk ...
Hormonal therapies are effective for recurrent and advanced prostate cancer, with PSA levels crucial for risk stratification. Combination hormone therapy is advised for metastatic prostate cancer, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results